Cardialen, Inc
http://www.cardialen.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cardialen, Inc
Dealmaking Quarterly Statistics, Q4 2022
During Q4, biopharma merger and acquisition value reached $35.7bn and drew in $62.1bn in potential deal value from alliances. Device company M&A values reached $19.2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $4.8bn.
Start-Up Previews, June 2016
In this month's issue of Start-Up, we profile Ariste Medical, BioDirection, Cardialen and Homology Medicines.
Cardialen Inc.
Cardialen's hybrid implantable pacemaker/defibrillator for atrial fibrillation monitors the heart beat by beat. At the first sign of arrhythmia it delivers a low-level electrical pulse to convert the patient's irregularity back to a normal heart rhythm.
Cardialen Inc.
Cardialen's hybrid implantable pacemaker/defibrillator for atrial fibrillation monitors the heart beat by beat. At the first sign of arrhythmia it delivers a low-level electrical pulse to convert the patient's irregularity back to a normal heart rhythm.
Company Information
- Industry
-
Medical Devices
- Implantable Devices
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice